New paradigm in biotechnology unfolding, due to phylomers exceptional folding abilities!
* Phylogica demonstrates biological activity for its lead compounds in its Rheumatoid Arthritis (RA) program
* Project funded by A$2.3m Commercial Ready Grant
* Phylomers now proven to work for disease targets both inside and outside the cell.
They preferentially bind to the CD40 target as good or better than well characterised antibodies specific for CD40. Would be interested to see a cost comparison of these compounds side by side, phylomers should be alot less pricey.
More at http://www.asx.com.au/asxpdf/20071010/pdf/31516w48lx96v3.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |